BCBS Massachusetts LINX TIF Coverage Prior Auth

Coverage and Medical Necessity Criteria

MSA (LINX) Medical Necessity

MEDICALLY NECESSARY when ALL of the following are met:

Duration and severity: Patient has a history of severe GERD for >= 1 year with daily symptoms>= 1 year

Conservative therapy failure: Patient has tried and failed optimal non-surgical management including lifestyle modification, weight loss if indicated, and daily proton pump inhibitor use for >= 6 months>= 6 months

Objective evidence: Patient has proven gastroesophageal reflux by either endoscopy or ambulatory pH monitoring

Esophageal function: Patient has evidence of adequate peristalsis by manometry or barium esophagram

Absence of contraindications: None of the following contraindications are present: morbid obesity (BMI >35); suspected or known metal allergies (eg, iron, nickel, titanium, stainless steel); LA Grade C or D esophagitis; scleroderma; esophageal stricture or gross anatomic abnormalities; suspected or confirmed esophageal or gastric cancer; prior esophageal or gastric surgery or endoscopic intervention

TIF Medical Necessity

MEDICALLY NECESSARY when ALL of the following are met:

Duration and severity: Patient has a history of severe GERD for >= 1 year with daily symptoms>= 1 year

Objective evidence: Patient has proven gastroesophageal reflux by endoscopy, ambulatory pH monitoring, or barium esophagram

Contraindications absent: None of the following contraindications are present: hiatal hernia >2 cm axial height and >2 cm greatest transverse dimension; morbid obesity (BMI >35); esophagitis grade C or D; Barrett's esophagus >2 cm; non-healing esophageal ulcer; fixed esophageal stricture or narrowing; portal hypertension/varices; active gastro-duodenal ulcer disease; gastric outlet obstruction or stenosis; gastroparesis; prior esophageal surgery; scleroderma; suspected or confirmed esophageal or gastric cancer

Investigational Procedures

The following interventions are considered INVESTIGATIONAL (NOT medically necessary):

Investigational procedures: Transesophageal radiofrequency (Stretta) to create submucosal thermal lesions of the gastroesophageal junction; endoscopic submucosal implantation of a prosthesis or injection of bulking agents (eg, polymethylmethacrylate beads, zirconium oxide spheres); delivery of thermal energy to the muscle of the lower esophageal sphincter and/or gastric cardia (eg, CPT 43257); endoscopic directed submucosal injections or endoscopic stent placement when used for GERD (eg, CPT 43201, 43212)

Coverage for magnetic sphincter augmentation (MSA) and transoral incisionless fundoplication (TIF) excludes members who have specific contraindications. Key exclusionary conditions include morbid obesity (BMI > 35), which precludes coverage for both procedures, and LA Grade C or D esophagitis (severe esophagitis).

Additional absolute contraindications are suspected or confirmed esophageal or gastric cancer, prior esophageal or gastric surgery or endoscopic interventions, and significant esophageal anatomic abnormalities such as strictures or fixed narrowing. Other listed exclusions relevant to TIF include a hiatal hernia > 2 cm in axial height and > 2 cm greatest transverse dimension, Barrett’s esophagus > 2 cm, non-healing esophageal ulcer, portal hypertension/varices, active gastroduodenal ulcer disease, gastric outlet obstruction or stenosis, and gastroparesis.

Metal hypersensitivity (suspected or known allergies to metals such as iron, nickel, titanium, or stainless steel) and systemic conditions that impair esophageal motility (for example, scleroderma) are also specified contraindications and therefore exclude members from coverage for MSA or TIF.

The following CPT codes are considered investigational and are therefore not medically necessary for treatment of gastroesophageal reflux disease: CPT 43201 (esophagoscopy with directed submucosal injection), CPT 43212 (esophagoscopy with placement of endoscopic stent), and CPT 43257 (EGD with delivery of thermal energy to the lower esophageal sphincter and/or gastric cardia).

Coding and Key Clinical Thresholds

Covered CPT Codes (when medical necessity criteria met)CPTCovered

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed

ICD-10-PCS Procedure CodesICD-10

0DV48ZZ	Restriction of Esophagogastric Junction, Via Natural or Artificial Opening Endoscopic.
0DV44CZ	Restriction of Esophagogastric Junction with Extraluminal Device, Percutaneous Endoscopic Approach

Investigational CPT CodesCPTExperimental

43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance.
43212	Esophagoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed).
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease

Required duration of PPI therapy

Required duration of daily PPI therapy>= 6 months

ContextPrerequisite for MSA (LINX) and TIF: patient must have tried and failed optimal non-surgical management including lifestyle modification and daily PPI use

Evidence sourceStated in medical necessity criteria for both MSA and TIF

Hiatal hernia size contraindication (for TIF)

Axial height threshold (hiatal hernia)> 2 cm

Greatest transverse dimension threshold> 2 cm

Prior Authorization, Submission, and Administrative Actions

Prior Authorization

Prior Authorization Required

Prior authorization requirements for services in this policy vary by setting and product. Inpatient procedures require precertification/preauthorization for all products. For outpatient procedures, prior authorization is required for Commercial Managed Care (HMO and POS) and Commercial PPO members. Note that this section does not explicitly state any additional prior authorization exceptions.

Inpatient: precertification/preauthorization IS REQUIRED for all products (see inpatient requirements).
Outpatient: Commercial Managed Care (HMO and POS) = prior authorization required; Commercial PPO = prior authorization required.
This section does NOT specify any prior authorization exemptions or alternative preauthorization pathways.

Step Therapy

Conservative Therapy Prerequisite

Members must have tried and failed optimal conservative (non-surgical) therapy prior to surgical or endoscopic procedures. Conservative therapy includes lifestyle modification, weight loss when indicated, and daily proton pump inhibitor (PPI) therapy for at least 6 months.

Clinical Background

Gastroesophageal reflux disease (GERD) results from reflux of stomach acid into the esophagus and ranges from intermittent, primarily symptomatic disease to chronic, severe disease that can cause mucosal injury (including Barrett’s esophagus) and, rarely, cancer. For patients with persistent, daily symptoms despite optimal medical management, procedural options exist to control reflux and improve quality of life.

This policy addresses device-based and endoscopic antireflux interventions as alternatives to continued medical therapy for selected patients with severe GERD. Candidates typically have had symptoms for ≥ 1 year, documented pathologic reflux by endoscopy or ambulatory pH testing, and have failed conservative management including lifestyle modification and daily proton pump inhibitor therapy for ≥ 6 months. Procedures discussed include magnetic sphincter augmentation (MSA/LINX) and transoral incisionless fundoplication (TIF); their use is guided by objective testing, esophageal function assessment, and absence of specified contraindications.

Definitions and Device/Procedure Descriptions

LINX Reflux Management System

DefinitionA laparoscopically implanted flexible band of interlinked titanium beads with magnetic cores placed around the gastroesophageal junction to augment the lower esophageal sphincter

MechanismMagnetic attraction between beads augments the LES to reduce reflux while allowing beads to separate during swallowing

RemovabilityDevice can be removed laparoscopically if severe adverse events occur or MRI is needed

Gastroesophageal reflux disease (GERD)

DefinitionReflux of stomach acid into the esophagus that causes symptoms and/or mucosal injury

Clinical spectrumRanges from mild intermittent symptoms to chronic, severe disease that can lead to complications such as Barrett esophagus and esophageal cancer

OpenPayer

Magnetic esophageal sphincter augmentation (LINX) and related endoscopic antireflux procedures

Coverage and Medical Necessity Criteria

Coding and Key Clinical Thresholds

Prior Authorization, Submission, and Administrative Actions

Clinical Background

Definitions and Device/Procedure Descriptions